TY - JOUR
T1 - TF-DUBTACs Stabilize Tumor Suppressor Transcription Factors
AU - Liu, Jing
AU - Yu, Xufen
AU - Chen, He
AU - Kaniskan, H. Ümit
AU - Xie, Ling
AU - Chen, Xian
AU - Jin, Jian
AU - Wei, Wenyi
N1 - Funding Information:
This work was supported in part by the NIH grants R35CA253027 (W.W.) and P30CA196521 (J.J.) and an endowed professorship from the Icahn School of Medicine at Mount Sinai (to J.J.). This work utilized the NMR Spectrometer Systems at Mount Sinai acquired with funding from National Institutes of Health SIG grants 1S10OD025132 and 1S10OD028504.
Publisher Copyright:
© 2022 American Chemical Society. All rights reserved.
PY - 2022/7/20
Y1 - 2022/7/20
N2 - Targeted protein degradation approaches have been widely used for degrading oncogenic proteins, providing a potentially promising therapeutic strategy for cancer treatment. However, approaches to targeting tumor suppressor proteins are very limited, and only a few agonists have been developed to date. Here, we report the development of a platform termed TF-DUBTAC, which links a DNA oligonucleotide to a covalent ligand of the deubiquitinase OTUB1 via a click reaction, to selectively stabilize tumor suppressor transcription factors. We developed three series of TF-DUBTACs, namely, FOXO-DUBTAC, p53-DUBTAC, and IRF-DUBTAC, which stabilize FOXO3A, p53, and IRF3 in cells, respectively, in an OTUB1-dependent manner. These results suggest that TF-DUBTAC is a generalizable platform to achieve selective stabilization of tumor suppressor transcription factors as a therapeutic means to suppress tumorigenesis.
AB - Targeted protein degradation approaches have been widely used for degrading oncogenic proteins, providing a potentially promising therapeutic strategy for cancer treatment. However, approaches to targeting tumor suppressor proteins are very limited, and only a few agonists have been developed to date. Here, we report the development of a platform termed TF-DUBTAC, which links a DNA oligonucleotide to a covalent ligand of the deubiquitinase OTUB1 via a click reaction, to selectively stabilize tumor suppressor transcription factors. We developed three series of TF-DUBTACs, namely, FOXO-DUBTAC, p53-DUBTAC, and IRF-DUBTAC, which stabilize FOXO3A, p53, and IRF3 in cells, respectively, in an OTUB1-dependent manner. These results suggest that TF-DUBTAC is a generalizable platform to achieve selective stabilization of tumor suppressor transcription factors as a therapeutic means to suppress tumorigenesis.
UR - http://www.scopus.com/inward/record.url?scp=85134721028&partnerID=8YFLogxK
U2 - 10.1021/jacs.2c04824
DO - 10.1021/jacs.2c04824
M3 - Article
C2 - 35786952
AN - SCOPUS:85134721028
SN - 0002-7863
VL - 144
SP - 12934
EP - 12941
JO - Journal of the American Chemical Society
JF - Journal of the American Chemical Society
IS - 28
ER -